< Back to all news
13 May 2024

Revolutionizing Liver Disease Prognosis: Insights from Vibration-Controlled Transient Elastography

Welcome to a new insightful episode of “Ask the Author”. Today, we’re honored to have Professor Vincent Wong with us, discussing his groundbreaking work titled “Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease,” recently published in JAMA.

In this enlightening discussion, Professor Wong delves into the background and context of their study. He highlights the prevalence of Metabolic Associated Fatty Liver Disease (MAFLD), affecting over 30% of the global population, necessitating the use of noninvasive tests (NITs) for disease assessment. Unlike previous studies focused solely on the correlation between NITs and liver histology, Professor Wong’s team aimed to demonstrate the prognostic value of NITs in monitoring disease progression and treatment response.

Their study, a multicenter cohort involving over 16,000 patients with MAFLD, showcased impressive numbers. Prospective data collection across 16 tertiary referral centers allowed for longitudinal analysis, with more than 10,000 patients undergoing multiple examinations. This comprehensive approach provided insights into the prognostic significance of changes in NITs over time.

The results are nothing short of revolutionary. Many existing NITs exhibited prognostic performance comparable to, if not superior to, liver histology. Notably, the Vibration-Controlled Transient Elastography (VCTE)-based Agile 3+ and Agile 4 scores stood out, boasting time-dependent area under the curve values nearing 90%. Furthermore, a 20% or greater change in liver status measurement translated into significant alterations in the incidence of liver-related events, validating NITs as effective monitoring tools.

Professor Wong emphasizes the transformative impact of these findings on the field. With growing evidence supporting the efficacy of NITs in predicting liver-related events and monitoring disease progression, the need for liver biopsy for prognostication diminishes. As regulatory bodies consider NITs as surrogate endpoints, patients stand to benefit from reduced reliance on invasive procedures, both in research and routine clinical care.

In conclusion, Professor Wong’s study heralds a new era in liver disease management, where noninvasive tests serve as reliable indicators of prognosis. With these insights, medical practitioners can navigate the complexities of MAFLD with greater confidence and precision, ultimately improving patient outcomes.

We extend our heartfelt congratulations to Professor Wong and his team for their remarkable contribution to the field. Stay tuned for more enlightening discussions on cutting-edge medical research.

Prof. Vincent Wong answering to the questions of Professor Jean-François Dufour.

< Back to all news
1 May 2024

Unlocking Insights: Highlights from HCC Day 2024

Dear Medical Colleagues,

In the ever-evolving landscape of hepatocellular carcinoma (HCC) management, staying abreast of the latest advancements is paramount. Fortunately, the recent HCC Day 2024 provided an invaluable platform for knowledge exchange, featuring esteemed international experts who shared groundbreaking insights and strategies in the fight against HCC.

We are excited to announce that the video content from this exceptional event is now available for viewing. Delve into a wealth of expertise and innovation by accessing the recordings at HCC Day 2024 webcast.

Here are just a few highlights from the keynote presentations:

  1. Selecting Systemic Therapy for HCC – Dr. A. Saborowski offers invaluable guidance on navigating the complex landscape of systemic therapy selection, providing practical insights for optimizing patient outcomes.
  2. TACE with I/O for HCC – Dr. R. Lencioni explores the promising frontier of combining transarterial chemoembolization (TACE) with immunotherapy, shedding light on novel approaches to HCC treatment.
  3. Combining Chemotherapy and Immunotherapy for Biliary Tract Cancer – Dr. K. Kelley shares groundbreaking research on the integration of chemotherapy and immunotherapy as a first-line approach for biliary tract cancer, offering new hope for patients facing this challenging disease.
  4. Systemic Therapies in Phase 2 to Treat HCC – Dr. R. Finn provides invaluable insights into emerging systemic therapies in phase 2 trials, highlighting potential game-changers in the field of HCC management.
  5. Preventing HCC Recurrence after Curative Therapy – Dr. P. Galle presents strategies for preventing HCC recurrence following curative therapy, addressing a critical aspect of long-term patient care.

Whether you’re a seasoned oncologist, a hepatologist, or a healthcare professional with an interest in HCC, these presentations are a must-watch. Gain access to cutting-edge research, clinical strategies, and expert perspectives that can inform and enhance your practice.

Don’t miss out on this unparalleled opportunity to expand your knowledge and elevate patient care. Click here to access the full spectrum of presentations from HCC Day 2024, thanks to Klewel audiovisual, streaming and webcasting services.

Quick recap of the HCC Day 2024.

Yours in advancing HCC care,

Professor Jean-François Dufour / NASH Foundation


< Back to all news
2 January 2024

Happy new year!

Everyone at the Swiss NASH Foundation wishes you a happy and healthy new year 2024!

< Back to all news
2 January 2024

Video available for the International NASH Symposium – 2023 a pivotal year for NASH

You can find the talks of the International NASH Symposium – 2023 a pivotal year for NASH now on our YouTube Channel.

< Back to all news
12 November 2023

International NASH Symposium 2023

We welcome you to the International NASH Symposium 2023 in Bern, Switzerland and online on the 30th November 2023!

Have a look at the agenda or register here to attend online. if you want to join the event in Bern please send us an email. Looking forward seeing you all soon!

< Back to all news
14 June 2022

#NASHday 2022!

Thank you!

We want to thank everyone participating in this years International NASH Day. We had great talks and discussions and we look forward to participating in 2023! Shortly we will publish the talks here from our webinar.

< Back to all news
4 May 2022

International Nash Day ahead

On June 6th the International Nash Day organised by the Global Liver Institute is happening and we from the Swiss Nash Foundation are taking part as well!

Agenda and speakers will follow soon!

< Back to all news
1 November 2021

AASLDs Liver Meeting 2021 is coming up!

From November 12th till 15th 2021 the annual Liver Meeting organised by the AASLD – American Association for the Study of Liver Diseases is coming up and of course we will attend this year as well. Please follow us on Twitter where will discuss and chat during the conference.

Various liver topics will be discussed and you can filter for the NASH and NAFLD talks here

Filter for NASH and NAFLD

At the moment you will find 9 talks and workshops all around NASH and NAFLD.

< Back to all news
6 September 2021

Omega 3 and NASH

< Back to all news
11 August 2021

Call for Submission: Research grants of the Swiss NASH Foundation

Application for Research Grants of the Swiss NASH Foundation

In 2021, the Swiss NASH Foundation will for the first time award research grants for original research proposals. 

Eligible are individuals or groups who plan to conduct a research project in Switzerland or in collaboration with a Swiss group, in the field of non-alcoholic fatty liver disease. 

The aim of the grant of the Swiss NASH Foundation is to further cutting edge research in the field of non-alcoholic liver disease with a focus on interdisciplinary approaches. Research should have a clinical focus or clear clinical application.


  • An original research project in the field of non-alcoholic fatty liver disease which will commence within the calendar year of 2022 (date of IRB/EC approval).
  • Individual authors or groups may apply.
  • Research activities were conducted mainly in Switzerland or in collaboration with a Swiss group.
  • Winners agree to participate in producing a short video and infographic on their research project in collaboration with members of the Swiss NASH social media team. These materials will be disseminated on the Swiss NASH social media channels.

Selection of the winner(s)

The winner(s) will be selected by an independent international panel of experts in the field of non-alcoholic liver disease. The winner(s) will be announced after the Swiss NASH Foundation Board Meeting in December 2021.

Required documents

  • Letter of motivation (max. 1 page)
  • Project description (max. 3 pages) covering the following: Aim, Methods, Significance, Timeline of the project, Budget, Role of the applicant in the project 
  • Curriculum Vitae

Documents should be submitted in English as a single PDF file by 15.09.2021 end of day (CET) to

info at

Aim of the Foundation

The Swiss NASH Foundation was launched in October 2019 in Bern, Switzerland. The Swiss NASH Foundation is a non-profit organization committed to the dissemination of knowledge and raising of awareness about NASH. Through funding cutting edge research projects as well as increasing knowledge and awareness about NASH, the Foundation aims at contributing to treatment discovery as well as improving patients’ quality of life.